IGHV3OR16-17

Across TCGA pan-cancer cohorts, IGHV3OR16-17 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated IGHV3OR16-17 data layer compared with 19 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher IGHV3OR16-17 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated IGHV3OR16-17 expression acts as an unfavorable survival marker.

BLCA, OV, and COAD are the cancer types where IGHV3OR16-17 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	0.077	0.626	<.001	39	view →
OV	OS	Median	II,III,IV	0.330	0.843	.002	18	view →
COAD	DFS	Median	II,III,IV	0.223	0.662	.022	12	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

IGHV3OR16-17–BLCA (DFS)

Open the BLCA breakdown →